ClinStar to Present at Outsourcing in Clinical Trials Europe

ClinStar, LLC, an established clinical research organization providing clinical development services in the emerging markets of Russia and Eastern Europe to the biopharmaceutical industry, announced today that President and CEO David Passov will present at Outsourcing in Clinical Trials Europe conference May 8-9 at Mövenpick Hotel Zürich-Regensdorf in Zürich, Switzerland.

According to Mr. Passov, “Patient recruitment rates in Russia & parts of Eastern Europe are up to 20 times faster than the West and study start-up averages only three months, much swifter than start-up timelines one can expect in other emerging markets.” “With results like these,” says Mr. Passov, “it’s no surprise that the biopharmaceutical industry is embracing the undeniable benefits of conducting clinical research studies in emerging markets such as Russia & Eastern Europe. In 2011, thirty-three percent of all drugs approved by FDA & 48% of all drugs approved by EMEA included data from clinical trials in Russia & parts of Eastern Europe.”

Despite these advantages and more, however, many biopharmaceutical organizations still have negative perceptions of working in this region due to fear of prolonged study start-up times and unknown regulatory and logistics requirements.

During the presentation scheduled for Tuesday, May 8 at 11:30 a.m., Mr. Passov will explore perceptions and comparisons of emerging markets and discuss how to navigate cultural and regulatory challenges in the region in order to optimize patient recruitment.

About ClinStar, LLC

ClinStar is one of the most prominent clinical research organizations in the emerging markets of Eastern Europe and the Baltics with more than 12 years of expertise in Phase I-IV clinical research studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 260 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at